What actually happens in your brain when you change your mind? Imagine a game show where the host asks the contestant to randomly pick one option out of three: A, B or C. Sep 7, 2025 0 24
Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, according to data ... Sep 7, 2025 0 22
First-in-human trial shows promising results for antibody-drug conjugate in relapsed small cell lung cancer A first-in-human Phase I study of SHR-4849 (IDE849), a Delta-like ligand 3 (DLL3)-directed antibody-drug conjugate (ADC), demonstrated manageable safety and early signs of anti-tumor activity in patients with relapsed small ... Sep 7, 2025 0 29
Higher blood pressure in childhood linked to earlier death from heart disease in adulthood Blood pressure matters at all ages. Children with higher blood pressure at age 7 may be at an increased risk of dying of cardiovascular disease by their mid-50s, according to preliminary research presented at the American ... Sep 7, 2025 0 24
AI helps older adults report accurate blood pressure readings at home Artificial intelligence (AI) voice agents helped older adults with high blood pressure to accurately report their blood pressure readings and improved blood pressure management, according to preliminary research presented ... Sep 7, 2025 0 19
What suicidal teens say matters most to them Why would a suicidal teenager choose to live? It's not the kind of question most of us ever want to ask. Suicide is the third leading cause of death among 15–29-year-olds worldwide. Much of the research and media coverage ... Sep 7, 2025 0 20
Intake of low-, no-calorie sweeteners tied to faster cognitive decline Consumption of low- and no-calorie sweeteners (LNCSs) is associated with faster cognitive decline, according to a study published online Sept. 3 in Neurology. Sep 7, 2025 0 53
Ivonescimab + chemotherapy improves progression-free survival in patients with EGFR+ NSCLC Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in patients with advanced non-small ... Sep 7, 2025 0 36
Crizotinib fails to improve disease-free survival in resected early-stage ALK+ non-small cell lung cancer Crizotinib, an approved treatment for advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC), did not improve disease-free survival (DFS) when given as adjuvant therapy in patients with surgically resected early-stage ... Sep 7, 2025 0 21
Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC Zidesamtinib, an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) designed to be highly selective, brain-penetrant, and TRK-sparing, demonstrated clinically meaningful activity and durability in patients ... Sep 7, 2025 0 18
